Form 4: Silence Therapeutics Director and 10% Owner Increases Stake with Significant Share Purchases

Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, has significantly increased his direct beneficial ownership through multiple American Depositary Share acquisitions in July 2025.

Summary

• Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc (SLN), acquired a total of 62,457 American Depositary Shares (ADS) across three separate transactions in July 2025.
• On July 7, 2025, 7,937 ADS were purchased at a price of $5.65 per share.
• On July 8, 2025, an additional 24,387 ADS were purchased at a price of $5.94 per share.
• On July 9, 2025, a further 30,133 ADS were purchased at a price of $6.00 per share.
• Each American Depositary Share is immediately convertible into three ordinary shares for no consideration, meaning these transactions effectively represent the acquisition of 187,371 ordinary shares.
• Following these transactions, Richard Ian Griffiths' direct beneficial ownership in Silence Therapeutics plc increased to 11,687,365 ordinary shares.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's prospects.

Positives

• A Director and 10% Owner, Richard Ian Griffiths, has increased his stake in the company, signaling strong confidence in Silence Therapeutics' future prospects.
• The acquisition of 62,457 American Depositary Shares (equivalent to 187,371 ordinary shares) represents a substantial investment by an insider.

Future Outlook

The document does not provide forward-looking statements or guidance, as it is a report of past insider transactions.

Management Comments

• The filing is signed by Richard Ian Griffiths, the reporting person.

Industry Context

Insider buying, particularly by a director and significant owner, is generally viewed as a positive signal in the biotechnology and pharmaceutical industry, indicating management's belief in the company's pipeline, strategic direction, or undervaluation.

Comparison to Industry Standards

• Insider buying is a common occurrence across industries, and the scale of this acquisition by a 10% owner and director is notable, often interpreted as a strong vote of confidence in the company's future performance.
• While specific comparable companies or projects are not detailed in this Form 4, such insider activity is generally seen as a more positive indicator than insider selling, which might suggest concerns about future prospects.

Related Party Transactions

• Acquisition of 62,457 American Depositary Shares (equivalent to 187,371 ordinary shares) by Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, through open market purchases.

Stakeholder Impact

• Shareholders: The insider buying could instill greater confidence among existing shareholders and potentially attract new investors, as it signals management's belief in the company's value.
• Employees: While not directly impacted, a stronger share price and positive market sentiment can indirectly benefit employees through stock options or general company morale.

Key Dates

Recommendation

Keywords

Silence Therapeutics, SLN, Form 4, insider buying, share purchase, director, 10% owner, American Depositary Shares, ordinary shares, equity acquisition